Pluristem therapeutics inc (PSTI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period

-28,776

-31,347

-33,660

-35,307

-36,528

-27,981

-27,527

-26,126

-24,161

-30,494

-28,875

-27,814

-27,003

-26,342

-23,694

-23,246

-22,336

-22,359

-24,642

-24,677

-25,578

-27,628

-28,088

-26,932

-27,726

-24,130

-21,915

-21,155

-18,300

-23,272

-14,296

-14,794

-14,384

-6,344

-13,652

-10,848

0

0

0

Depreciation

1,697

1,814

1,927

1,962

1,987

1,996

2,006

2,018

2,043

2,090

2,134

2,177

2,206

2,229

2,211

2,150

2,166

2,103

2,073

2,074

1,984

1,967

1,939

1,902

1,857

1,694

1,364

1,033

715

710

468

435

400

168

339

312

0

0

0

Loss from sale of property and equipment, net

-

-

-

-

-

-

-

-

-

-

-

-72

-80

-79

-81

-82

-17

-19

-17

-20

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-8

0

0

0

Linkage differences and interest on long-term restricted lease deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accretion of discount, amortization of premium and changes in accrued interest of marketable securities

-

-

-

-

-

-

-

11

214

201

81

35

-323

-414

-283

-114

21

214

305

213

1,248

962

767

1,282

252

566

670

154

360

70

56

17

0

0

0

-

-

-

-

Gain from sale of investments of available-for-sale marketable securities

-

-

-

-

-

-

-

8,440

8,766

1,270

1,286

362

-80

-419

-432

-419

-303

-467

-256

-290

545

760

568

727

-61

213

183

26

-18

-20

-12

3

0

0

0

-

-

-

-

Other-than-temporary loss of available-for-sale marketable securities

-

-

-

-

-

-

-

850

1,617

1,617

1,617

767

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation to employees, directors and non-employee consultants

3,199

4,581

4,683

5,146

5,602

5,636

6,372

6,548

5,975

5,863

4,680

3,662

3,288

2,409

2,650

3,073

3,507

3,869

3,900

4,052

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation to employees, directors and non-employees consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

4,522

1,862

3,904

3,325

0

0

0

Stock compensation to investor relations consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

1

77

120

155

0

0

0

Decrease (increase) in accounts receivable from the IIA

-

0

34

-

-

-90

12

-978

278

-115

-434

-1,192

138

137

40

537

-24

-8

-32

-572

-79

-392

-1,972

1,990

-435

-461

1,474

70

-841

1,036

900

230

1,195

-337

-155

-656

0

0

0

Increase in other current assets and other long-term assets

188

-129

354

397

70

1,576

415

59

-153

354

969

731

246

-258

-600

-1,395

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease (increase) in other accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease (increase) in prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

321

308

194

-269

-41

257

254

273

0

0

0

Decrease in trade payables

-1,112

-200

760

-863

1,005

257

604

1,212

210

-947

-666

-701

-113

1,036

860

-77

-618

-747

-903

-566

-164

-3

21

1,257

1,711

-356

594

1,335

-590

1,755

651

-424

314

200

367

455

0

0

0

Decrease in other accounts payable, accrued expenses, other current liabilities and other long-term liabilities

-1,031

-1,134

-1,480

86

-768

933

1,808

1,600

1,194

1,147

-108

138

1,371

-414

1,346

1,225

1,372

519

-1,105

-949

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in operating lease right-of-use asset and liability, net and effect of exchange rate differences

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in other accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

271

341

547

375

0

0

0

Decrease in deferred revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,847

-2,941

-3,036

-379

-379

-379

-379

0

-379

-380

-480

-958

-679

-685

3,890

-757

4,284

0

0

0

-

-

-

-

Decrease in advance payment from United Therapeutics Corporation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-93

-124

-143

-148

-154

-137

-154

-138

-146

-306

-302

-603

-1,183

-942

597

-1,041

1,576

0

0

0

-

-

-

-

Decrease in interest receivable on short-term deposits

-164

-47

-37

-68

-23

40

180

128

343

52

-23

24

-8

-14

62

25

17

-10

-79

-35

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-15

0

0

0

Linkage differences and interest on short and long-term deposits and restricted bank deposits

-

0

0

-

-

-

-

5

12

-11

-8

-14

-12

-28

-30

-3

46

13

41

54

34

76

217

12

101

73

-161

-30

142

-66

-57

35

0

0

0

-

-

-

-

Accrued severance pay, net

-37

-24

-29

-24

70

51

150

145

69

89

-11

-8

-1

21

36

38

35

8

-18

-61

-109

-7

-27

49

68

-21

15

-11

-6

7

15

5

61

63

47

58

0

0

0

Net cash used by operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-20,917

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used by operating activities

-26,720

-26,222

-28,184

-29,453

-28,566

-28,135

-24,700

-21,380

-21,984

-21,930

-22,878

-21,611

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-4,504

-3,535

-1,606

-5,755

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment

179

174

116

239

340

350

371

342

237

290

381

378

575

552

789

1,750

1,728

1,750

1,666

831

775

956

1,382

1,573

2,498

2,140

2,793

4,309

3,414

4,817

3,279

1,480

1,603

402

715

962

0

0

0

Repayment of long-term deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from short-term deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

898

0

0

0

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

30

7

31

31

28

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

29

0

0

0

Proceeds from short-term deposits

7,003

908

1,584

-1,415

-25,508

-8,102

10,962

14,721

14,157

15,883

-4,581

-2,373

1,116

-16,487

-8,913

849

-26

3,805

-3,356

-16,061

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of (investment in) long-term deposits and restricted bank deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment in short-term deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

0

0

-

-

-

-

Repayment (investment) in long-term deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

0

0

-

-

-

-

Repayment of long-term restricted deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

6

0

15

13

0

0

0

Proceeds from sale of available-for-sale marketable securities

-

-

-

-

-

-

-

21,881

22,786

10,724

11,805

5,527

8,758

9,758

9,214

6,999

3,619

9,280

11,115

10,635

12,117

5,559

4,280

6,113

5,044

4,352

3,405

1,848

0

0

0

-

-

-

-

-

-

-

-

Proceeds from redemption of available-for-sale marketable securities

-

-

-

-

-

-

-

9

17

139

364

410

430

723

920

1,094

1,260

984

799

634

0

0

0

-

-

-

-

-

-

-

-

114

0

0

0

-

-

-

-

Investment in available-for-sale marketable securities

-

-

-

-

-

-

-

1,146

2,461

3,191

4,067

3,607

2,553

3,234

4,325

4,215

5,329

4,933

5,387

4,903

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from redemption of available-for-sale marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

Investment in available-for-sale marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

0

0

0

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

8,162

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-7,181

-1,080

-1,706

1,170

25,162

20,617

1,538

5,681

5,970

-8,477

12,328

4,355

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-29,567

-439

-33,020

-36

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds related to issuance of common stock, net of issuance costs

31,119

27,482

24,975

23,467

6,283

5,911

18,078

18,631

16,058

30,390

16,744

15,718

15,718

0

0

790

16,590

17,176

17,704

16,914

0

0

0

-

-

-

0

34,106

34,106

34,106

34,106

0

0

38,385

43,148

43,400

0

0

0

Exercise of warrants and options

-

-

-

8

42

45

1,285

1,202

1,168

1,171

30

10

10

5

5

17

53

57

194

287

0

0

0

-

-

-

1,319

2,198

2,096

2,469

1,697

632

0

0

0

-

-

-

-

Proceeds with respect to Israel-United States Binational Industrial Research and Development Foundation liability

-

-

-

107

107

107

96

88

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

17,898

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of long-term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

0

0

0

Net cash provided by financing activities

31,119

27,482

24,975

23,582

6,432

6,063

19,459

19,921

17,383

31,718

16,843

15,797

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

810

42,029

47,132

47,037

0

0

0

Increase in cash and cash equivalents and restricted cash

-2,782

180

-4,915

-4,701

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-85

2,386

-4,707

-16,403

-3,540

-2,013

5,143

18,133

5,306

2,335

-2,941

-4,514

-24,183

-18,922

-30,148

-382

16,216

-19,244

25,118

-33,440

-33,261

38,053

12,506

41,246

0

0

0

Increase (decrease) in cash and cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(a) Supplemental disclosure of cash flow activities:
Taxes paid due to non-deductible expenses

11

10

11

10

26

26

26

27

16

18

23

28

36

39

66

66

57

80

32

54

52

30

47

48

46

50

46

18

17

16

9

14

14

4

14

11

0

0

0

(b) Supplemental disclosure of non-cash activities:
Purchase of property and equipment on credit

84

38

51

54

134

179

147

171

123

68

19

88

-50

30

59

126

803

672

589

612

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash included in Restricted cash and short-term bank deposits

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash, cash equivalents and restricted cash shown in the consolidated statement of cash flows

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share consideration to contractor

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39

302

302

328

263

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment on credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

55

50

159

123

0

0

0

Receivables on account of shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock based compensation to contractor

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-